On October 19, 2022 Blueprint Medicines Corporation (Nasdaq: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, reported that it will host an Investor Day for analysts and investors on Tuesday, November 1, 2022 beginning at 8:30 a.m. ET in New York City (Press release, Blueprint Medicines, OCT 19, 2022, View Source [SID1234622193]). In addition, the company will report its third quarter 2022 financial results on Tuesday, November 1, 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Investor Day will feature presentations by Blueprint Medicines’ management team, which will review the company’s plans to leverage the knowledge, skills and infrastructure of its fully integrated business to bring the promise of precision medicine to patients on a more expansive scale. In addition, the Investor Day will feature a panel discussion with key opinion leaders in the fields of mastocytosis, allergy and immunology.

A live webcast of the event will be available under "Events and Presentations" in the Investors & Media section of Blueprint Medicines’ website at View Source A replay of the webcast will be archived on Blueprint Medicines’ website for 90 days following the event.